Trial Profile
A phase IIB/III pivotal study of KAND567
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs KAND-567 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2024 New trial record